Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for prostate cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
Comparison of Quantitative Apparent Diffusion Coefficient Parameters with Prostate Imaging Reporting and Data System V2 Assessment for Detection of Clinically Significant Peripheral Zone ProstateCancer 28840280 2018 11 13 2366-0058 43 5 2018 May Abdominal radiology (New York) Abdom Radiol (NY) Comparison of quantitative apparent diffusion coefficient parameters with prostate imaging reporting and data system V2 assessment for detection of clinically significant peripheral zone prostatecancer (...) . 1237-1244 10.1007/s00261-017-1297-y To compare diagnostic performance of PI-RADSv2 with ADC parameters to identify clinically significant prostatecancer (csPC) and to determine the impact of csPC definitions on diagnostic performance of ADC and PI-RADSv2. We retrospectively identified treatment-naïve pathology-proven peripheral zone PC patients who underwent 3T prostate MRI, using high b-value diffusion-weighted imaging from 2011 to 2015. Using 3D slicer, areas of suspected tumor (T) and normal
Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk ProstateCancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian ProstateCancer Group 12 Trial 29395502 2018 05 19 1873-7560 73 6 2018 Jun European urology Eur. Urol. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk ProstateCancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian ProstateCancer Group 12 Trial. 870-876 S0302-2838(18)30021-6 10.1016 (...) /j.eururo.2018.01.012 Adjuvant chemotherapy is standard treatment for other solid tumours, but to date has not proven effective in prostatecancer. o evaluate whether six cycles of docetaxel alone improve biochemical disease-free survival after radical prostatectomy for high-risk prostatecancer. Open-label, randomised multinational phase 3 trial. Enrolment of 459 patients after prostatectomy. high-risk pT2 margin positive or pT3a Gleason score ≥4+3, pT3b, or lymph node positive disease Gleason score ≥3
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in ProstateCancer 29522362 2018 04 29 1527-7755 36 11 2018 Apr 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in ProstateCancer. 1088-1095 10.1200/JCO.2017.75.3335 Purpose (...) Chemohormonal therapy with docetaxel and androgen deprivation therapy (ADT+D) for metastatic hormone-sensitive prostatecancer improves overall survival as compared with androgen deprivation therapy (ADT) alone. We compared the quality of life (QOL) between patients with metastatic hormone-sensitive prostatecancer who were treated with ADT+D and those who were treated with ADT alone. Methods Men were randomly assigned to ADT+ D (six cycles) or to ADT alone. QOL was assessed by Functional Assessment
Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade ProstateCancer 29478736 2018 02 26 1873-7560 2018 Feb 22 European urology Eur. Urol. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade ProstateCancer. S0302-2838(18)30098-8 10.1016/j.eururo.2018.01.043 The consequences of low prostate-specific antigen (PSA) in high-grade (Gleason 8-10) prostatecancer are unknown. To evaluate the clinical implications and genomic features of low (...) -PSA, high-grade disease. This was a retrospective study of clinical data for 494 793 patients from the National Cancer Data Base and 136 113 patients from the Surveillance, Epidemiology, and End Results program with cT1-4N0M0 prostatecancer (median follow-up 48.9 and 25.0 mo, respectively), and genomic data for 4960 patients from the Decipher Genomic Resource Information Database. Data were collected for 2004-2017. Multivariable Fine-Gray and Cox regressions were used to analyze prostatecancer
ProstateCancer: Screening USPSTF Final Prostate Screening Recommendations Text Size: ProstateCancer Screening Final Recommendation Providing clinicians and patients with important information to help guide decisions about prostatecancer screening. The U.S. Preventive Services Task Force (USPSTF or Task Force) has reviewed the evidence on PSA-based screening for prostatecancer and published its final recommendation. The Task Force is deeply committed to a clear and transparent recommendation (...) development process and this final recommendation was informed by comments we received on our draft recommendation from experts, stakeholders and the public. The Task Force recommends men ages 55 to 69 make an individual decision about prostatecancer screening with their clinician. The Task Force recommends against routine screening for men age 70 and older. Final Recommendations Men ages 55–69 For men aged 55 to 69 years, the decision to undergo periodic prostate-specific antigen (PSA)–based screening
A Web-Based Intervention to Reduce Distress After ProstateCancer Treatment: Development and Feasibility of the Getting Down to Coping Program in Two Different Clinical Settings 29712628 2018 11 14 2369-1999 4 1 2018 Apr 30 JMIR cancer JMIR Cancer A Web-Based Intervention to Reduce Distress After ProstateCancer Treatment: Development and Feasibility of the Getting Down to Coping Program in Two Different Clinical Settings. e8 10.2196/cancer.8918 Distress after prostatecancer treatment (...) is a substantial burden for up to one-third of men diagnosed. Physical and emotional symptoms and health service use can intensify, yet men are reticent to accept support. To provide accessible support that can be cost effectively integrated into care pathways, we developed a unique, Web-based, self-guided, cognitive-behavior program incorporating filmed and interactive peer support. To assess feasibility of the intervention among men experiencing distress after prostatecancer treatment. Demand, acceptability
Hedgehog in prostatecancer explained 29854872 2018 11 14 2331-4737 5 3-4 2018 Mar Oncoscience Oncoscience Hedgehog in prostatecancer explained. 67-68 10.18632/oncoscience.405 Buttyan Ralph R The Vancouver Prostate Centre, Vancouver BC V6H 3Z6 Canada. Li Na N The Vancouver Prostate Centre, Vancouver BC V6H 3Z6 Canada. Massah Shabnam S The Vancouver Prostate Centre, Vancouver BC V6H 3Z6 Canada. eng Editorial 2018 04 29 United States Oncoscience 101636666 2331-4737 Androgen Receptors Gli (...) Hedgehog Steroid Receptors prostatecancer CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 04 12 2018 04 21 2018 6 2 6 0 2018 6 2 6 0 2018 6 2 6 1 epublish 29854872 10.18632/oncoscience.405 405 PMC5978441 Eur J Cancer. 2006 Mar;42(4):437-45 16406505 Prostate. 2014 Oct;74(14 ):1400-10 25132524 Cancer Chemother Pharmacol. 2016 Dec;78(6):1297-1304 27826729 Cell Mol Life Sci. 2000 Nov;57(12 ):1720-31 11130178 Oncogene. 2018 Apr;37(17 ):2313-2325 29429990 Horm Cancer. 2014
Germline genetic testing in prostatecancer â€“ further enrichment in variant histologies? 29854870 2018 11 14 2331-4737 5 3-4 2018 Mar Oncoscience Oncoscience Germline genetic testing in prostatecancer - further enrichment in variant histologies? 62-64 10.18632/oncoscience.403 Markowski Mark C MC Departments of Oncology and Urology, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD 21287, USA. Antonarakis Emmanuel S ES Departments of Oncology and Urology, Johns Hopkins Sidney Kimmel (...) Cancer Center, Baltimore, MD 21287, USA. eng Editorial 2018 04 29 United States Oncoscience 101636666 2331-4737 CONFLICTS OF INTEREST The authors declare no potential conflicts of interest. 2018 03 29 2018 03 29 2018 6 2 6 0 2018 6 2 6 0 2018 6 2 6 1 epublish 29854870 10.18632/oncoscience.403 403 PMC5978447 N Engl J Med. 2016 Aug 4;375(5):443-53 27433846 Cell. 2015 May 21;161(5):1215-1228 26000489 Eur Urol. 2017 Jul;72 (1):34-42 28259476 Cell. 2015 Nov 5;163(4):1011-25 26544944 Eur Urol. 2018 May;73
Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With ProstateCancer 29761176 2018 11 14 2472-1972 2 5 2018 May 01 Journal of the Endocrine Society J Endocr Soc Androgen Deprivation Therapy Is Associated With Prolongation of QTc Interval in Men With ProstateCancer. 485-496 10.1210/js.2018-00039 Androgen deprivation therapy (ADT) for prostatecancer (PCa) is associated with increased cardiovascular mortality and sudden cardiac death, with some events (...) Medical School, Boston, Massachusetts. Travison Thomas G TG Program on Aging, Hebrew SeniorLife, Roslindale, Massachusetts. Kantoff Philip W PW Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, New York. Nguyen Paul L PL Department of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Taplin Mary-Ellen ME Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Kibel Adam S AS Division
Men feel physically and psychologically ill-prepared for prostatecancer surgery NIHR DC | Signal - Men feel physically and psychologically ill-prepared for prostatecancer surgery Dissemination Centre Discover Portal NIHR DC Discover Men feel physically and psychologically ill-prepared for prostatecancer surgery Published on 28 November 2017 Following prostatecancer surgery men often experience physical changes, such as urinary incontinence and erectile dysfunction, causing negative emotions (...) and distress. This review found that men felt poorly prepared – psychologically and physically – for the changes they might experience after surgery. Surgery was often described as "life-changing", and men described worrying about their future. NICE recommend that men and their partners/carers are fully informed about prostatecancer treatment options and their possible complications, and are supported in decision-making. This includes having access to psychosexual support at any time. This global review
MRI scan before biopsy could detect more prostatecancer NIHR DC | Signal - MRI scan before biopsy could detect more prostatecancer Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal MRI scan before biopsy could detect more prostatecancer Published on 7 March 2017 In men with a raised prostate specific antigen (PSA) blood test, which can be a sign of prostatecancer, MRI scanning before standard biopsy could allow more targeted biopsies and increase diagnosis of medium and high (...) -risk prostatecancer. In this NIHR-funded study, 576 men with suspected prostatecancer received a multi-parametric (MP)-MRI scan in addition to transrectal ultrasound-guided (TRUS) biopsy. They also had template mapping (TPM) biopsy of the entire prostate to reliably diagnose cancer. Neither MP-MRI scan nor TRUS-biopsy were entirely accurate. However, if MP-MRI is used as an initial test, followed by TRUS-biopsy targeted at areas identified on the scan, 18% more cancers could be detected than
Bone-targeting drugs improve quality of life, but not survival in prostatecancer that has spread to bone NIHR DC | Signal - Bone-targeting drugs improve quality of life, but not survival in prostatecancer that has spread to bone Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Bone-targeting drugs improve quality of life, but not survival in prostatecancer that has spread to bone Published on 27 September 2016 The drug zoledronic acid delayed the onset of bone complications (...) by two months in men with prostatecancer that had spread to the bone. Though it did not increase overall survival, it improved quality of life by reducing important complications such as fractures and spinal cord compression. The radioactive drug strontium-89 was also tested and delayed the combined outcome of bone-related complications, pain or death by about one month. It also had no effect on overall survival or the number of bone complications. Both treatments were compared with chemotherapy
Large ten-year trial on treatment of localised prostatecancer will aid management decisions NIHR DC | Signal - Large ten-year trial on treatment of localised prostatecancer will aid management decisions Dissemination Centre Discover Portal NIHR DC Discover NIHR Signal Large ten-year trial on treatment of localised prostatecancer will aid management decisions Published on 15 September 2016 New, long-term research indicates that active monitoring, with prompt treatment if needed, may (...) be a better option than radical surgery or radiotherapy for many men who have prostatecancer if it’s confined to the prostate gland. In the ProtecT trial, after an average of ten years, few men died of prostatecancer and there was no difference in survival between men receiving active monitoring and those who had radical treatments (which caused unpleasant side effects). But active monitoring did increase the risk of cancer progressing or spreading to other parts of the body. Longer follow-up will help
Apalutamide (Erleada) - prostatecancer Drug Approval Package: ERLEADA (apalutamide) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: ERLEADA (apalutamide) This review package includes Clinical Study Reports as part of a pilot project. The Clinical Study Report section provides information for pivotal clinical trials, not for all studies in the application. Company: Janssen Biotech Application Number: 210951 Orig 1 Approval Date: 02/14/2018 Persons
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostatecancer (LATITUDE): an international, randomised phase 3 trial 29326030 2018 02 07 1474-5488 19 2 2018 Feb The Lancet. Oncology Lancet Oncol. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive (...) prostatecancer (LATITUDE): an international, randomised phase 3 trial. 194-206 S1470-2045(17)30911-7 10.1016/S1470-2045(17)30911-7 In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostatecancer. Understanding the effects of treatments on patient-reported outcomes (PROs) and health-related quality of life (HRQOL
Chemohormonal Therapy in Metastatic Hormone-Sensitive ProstateCancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial 29384722 2018 04 21 1527-7755 36 11 2018 Apr 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Chemohormonal Therapy in Metastatic Hormone-Sensitive ProstateCancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. 1080-1087 10.1200/JCO.2017.75.3657 Purpose (...) Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostatecancer. Herein, we present the outcomes of the CHAARTED (Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in ProstateCancer) trial with more mature follow-up and focus on tumor volume. Patients and Methods In this phase III study, 790 patients with metastatic hormone-sensitive prostatecancer were equally randomly
Salvage Pelvic Lymph Node Dissection After Fluciclovine Positron Emission Tomography/Computed Tomography Detected ProstateCancer Recurrence 29682612 2018 11 14 2379-9889 4 1 2018 Journal of endourology case reports J Endourol Case Rep Salvage Pelvic Lymph Node Dissection After Fluciclovine Positron Emission Tomography/Computed Tomography Detected ProstateCancer Recurrence. 59-61 10.1089/cren.2018.0011 Background: Multiple new systemic agents have been targeted to metastaticprostatecancer (...) risk cancer developed rapid biochemical recurrence. After salvage radiation, fluciclovine positron emission tomography (PET)/computed tomography (CT) scan showed a solitary pelvic lymph node metastasis. A robot-assisted laparoscopic pelvic lymph node dissection was carried out, with subsequent nadir of his prostate-specific antigen at 0.026. Conclusion: To our knowledge, this is the first report of salvage pelvic lymph node dissection after metastatic detection by fluciclovine PET/CT scan. Our
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. Background Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography-guided biopsy for prostate-cancer detection in men with a raised prostate-specific antigen level who have not undergone biopsy. However, comparative evidence is limited. Methods In a multicenter, randomized, noninferiority trial, we assigned men with a clinical suspicion of prostate (...) cancer who had not undergone biopsy previously to undergo MRI, with or without targeted biopsy, or standard transrectal ultrasonography-guided biopsy. Men in the MRI-targeted biopsy group underwent a targeted biopsy (without standard biopsy cores) if the MRI was suggestive of prostatecancer; men whose MRI results were not suggestive of prostatecancer were not offered biopsy. Standard biopsy was a 10-to-12-core, transrectal ultrasonography-guided biopsy. The primary outcome was the proportion of men
Effect of a Low-Intensity PSA-Based Screening Intervention on ProstateCancer Mortality: The CAP Randomized Clinical Trial. Importance: Prostatecancer screening remains controversial because potential mortality or quality-of-life benefits may be outweighed by harms from overdetection and overtreatment. Objective: To evaluate the effect of a single prostate-specific antigen (PSA) screening intervention and standardized diagnostic pathway on prostatecancer-specific mortality. Design, Setting (...) , and Participants: The Cluster Randomized Trial of PSA Testing for ProstateCancer (CAP) included 419 582 men aged 50 to 69 years and was conducted at 573 primary care practices across the United Kingdom. Randomization and recruitment of the practices occurred between 2001 and 2009; patient follow-up ended on March 31, 2016. Intervention: An invitation to attend a PSA testing clinic and receive a single PSA test vs standard (unscreened) practice. Main Outcomes and Measures: Primary outcome: prostatecancer
Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 ProstateCancer. Importance: The optimal treatment for Gleason score 9-10 prostatecancer is unknown. Objective: To compare clinical outcomes of patients with Gleason score 9-10 prostatecancer after definitive treatment. Design, Setting, and Participants: Retrospective cohort study in 12 tertiary centers (11 (...) in the United States, 1 in Norway), with 1809 patients treated between 2000 and 2013. Exposures: Radical prostatectomy (RP), external beam radiotherapy (EBRT) with androgen deprivation therapy, or EBRT plus brachytherapy boost (EBRT+BT) with androgen deprivation therapy. Main Outcomes and Measures: The primary outcome was prostatecancer-specific mortality; distant metastasis-free survival and overall survival were secondary outcomes. Results: Of 1809 men, 639 underwent RP, 734 EBRT, and 436 EBRT+BT. Median